Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of TAS-117 in advanced solid tumors
jRCT2080222728Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pifusertib in Nonhematologic neoplasms, clear cell ovarian cancer and endometrial cancer (EC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety, Tolerability and 2 more. Started Jan 2015; status: completed.
02
Drugs
pifusertib
03
Conditions
Nonhematologic neoplasmsclear cell ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2080222728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222728.